The Effects of Empagliflozin on Arterial Wall Characteristics

NCT03639545 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Vascular Stiffness
Hypoglycemic Agents
Diabetes Complications
Diabetes Mellitus, Type 1

Interventions

DRUG: Empagliflozin 25mg
DRUG: Metformin
DRUG: Empagliflozin/Metformin
DRUG: Placebos

Sponsor

University Medical Centre Ljubljana